Aktive Positionen von Karl Richard Gibson
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Ixchelsis Ltd.
 Ixchelsis Ltd. BiotechnologyHealth Technology Ixchelsis Ltd. develops oxytocin receptor antagonist for the treatment of premature ejaculation. It operates as a biotechnology company. The firm's product in pipeline IX-01 treats the male sexual health indication and premature ejaculation. The company was founded on July 27, 2011 by Gary John Muirhead, Lizbeth Anne Littlewood, Ian Howard Osterloh and Karl Richard Gibson and is headquartered in Sandwich, the United Kingdom. | Technik-/Wissenschafts-/F&E-Leiter | 27.07.2011 | - |
| Gründer | 27.07.2011 | - | |
| Sandexis LLP | Gründer | - | - |
Karriereverlauf von Karl Richard Gibson
Ausbildung von Karl Richard Gibson
| University of Cambridge | Doctorate Degree |
Statistik
International
| Vereinigtes Königreich | 4 |
Operativ
| Founder | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Sektoral
| Health Technology | 2 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Ixchelsis Ltd.
Ixchelsis Ltd. BiotechnologyHealth Technology Ixchelsis Ltd. develops oxytocin receptor antagonist for the treatment of premature ejaculation. It operates as a biotechnology company. The firm's product in pipeline IX-01 treats the male sexual health indication and premature ejaculation. The company was founded on July 27, 2011 by Gary John Muirhead, Lizbeth Anne Littlewood, Ian Howard Osterloh and Karl Richard Gibson and is headquartered in Sandwich, the United Kingdom. | Health Technology |
| Sandexis LLP |
- Börse
- Insiders
- Karl Richard Gibson
- Erfahrung